Large B-cell Lymphoma Clinical Trials

89 clinical trials for Large B-cell Lymphoma across international registries, including 47 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL — RECRUITING · PHASE2
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies — RECRUITING · PHASE1
• Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies — RECRUITING · PHASE1
• A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma — RECRUITING · PHASE2
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — RECRUITING · PHASE3
• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL — RECRUITING · PHASE2
• A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy — RECRUITING · PHASE2
• Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas — RECRUITING · PHASE1
• Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma — RECRUITING · PHASE2
• Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE3
• AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL — RECRUITING · PHASE3
• A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T — RECRUITING · PHASE2
• Glofitamab in Real Life — RECRUITING
• Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma — RECRUITING · PHASE1
• CAR-T Followed by Bispecific Antibodies — RECRUITING · PHASE2
• Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma — RECRUITING · PHASE2
• NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma — RECRUITING · PHASE1
• The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL — RECRUITING · PHASE2
• Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma — RECRUITING
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY OF KITE-753 VERSUS AXICABTAGENE CILOLEUCEL IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY LARGE B-CELL LYMPHOMA AFTER FIRST-LINE THERAPY — RECRUITING · PHASE3
• CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma — RECRUITING · PHASE2
• Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym — RECRUITING · PHASE2
• Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL — RECRUITING · PHASE2
• Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma — RECRUITING · PHASE2
• BHB & CAR-T for Lymphomas — RECRUITING · NA
• The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study — RECRUITING · PHASE2
• Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study — RECRUITING
• A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• Emapalumab Prevention of CAR-T Cell Associated Toxicities — RECRUITING · PHASE2
• Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — RECRUITING · NA
• Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel — RECRUITING · PHASE1
• UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies — RECRUITING · PHASE1
• Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma — RECRUITING · PHASE2
• A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL — RECRUITING · PHASE1
• T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) — RECRUITING · PHASE1
• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies — RECRUITING · PHASE1
• Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma — RECRUITING · PHASE1
• Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy — RECRUITING
• A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3) — RECRUITING
• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma — RECRUITING · PHASE2
• CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms — RECRUITING · PHASE1
• CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma — RECRUITING · PHASE2
• CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol — RECRUITING · PHASE2
• A PHASE III STUDY TO EVALUATE THE EFFICACY OF SUROVATAMIG COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PREVIOUSLY UNTREATED LARGE B-CELL LYMPHOMA (SOUNDTRACK D3) — NOT_YET_RECRUITING · PHASE3
• AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL — NOT_YET_RECRUITING · PHASE2
• GLORY: Glofit-GemOx With Liso-Cel For Lymphoma — NOT_YET_RECRUITING · PHASE2

Refine this search